Cargando…

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a cryptogenic chronic interstitial pneumonia with progressive fibrosis and a poor prognosis. A substantial number of epidemiological studies have been conducted in Europe and the United States (US). In contrast, in Japan, only one study reported the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondoh, Yasuhiro, Suda, Takafumi, Hongo, Yoshie, Yoshida, Manami, Hiroi, Shinzo, Iwasaki, Kosuke, Takeshima, Tomomi, Homma, Sakae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822670/
https://www.ncbi.nlm.nih.gov/pubmed/35135550
http://dx.doi.org/10.1186/s12931-022-01938-6
_version_ 1784646644425293824
author Kondoh, Yasuhiro
Suda, Takafumi
Hongo, Yoshie
Yoshida, Manami
Hiroi, Shinzo
Iwasaki, Kosuke
Takeshima, Tomomi
Homma, Sakae
author_facet Kondoh, Yasuhiro
Suda, Takafumi
Hongo, Yoshie
Yoshida, Manami
Hiroi, Shinzo
Iwasaki, Kosuke
Takeshima, Tomomi
Homma, Sakae
author_sort Kondoh, Yasuhiro
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a cryptogenic chronic interstitial pneumonia with progressive fibrosis and a poor prognosis. A substantial number of epidemiological studies have been conducted in Europe and the United States (US). In contrast, in Japan, only one study reported the prevalence of IPF (10.0 per 100,000 population) using clinical data (2003–2007) from one prefecture; thus, the nationwide prevalence of IPF remains unknown. This study aimed to estimate the nationwide prevalence of IPF in Japan using a nationwide claims database. METHODS: We extracted data from a Japanese claims database provided by Medical Data Vision (MDV database, April 2008–March 2019) containing data from approximately 28 million patients from 385 acute-care hospitals. Patients with IPF (those diagnosed with IPF at least once) from April 2017 to March 2018 were identified in the MDV database. The number of patients in the MDV database was extrapolated nationwide using the fourth NDB Open Data (April 2017–March 2018), and the prevalence was estimated using demographic data as denominators. The prevalence in the US, considering the same definition of IPF, was also calculated and compared with that in Japan. RESULT: The number of patients with IPF in the MDV database was 4278. The estimated nationwide number of patients in Japan was estimated to be 34,040 (mean age: 73 years, percentage of men: 73%), and the prevalence was 27 per 100,000 population. In comparison with that in the US, the prevalence was similar in men and relatively lower in women until the age of 75–79 years, and it was notably lower in both sexes aged ≥ 80 years. CONCLUSIONS: We report the nationwide IPF prevalence in Japan using data from claims databases for the first time. The prevalence estimated in this study was higher than that reported in a previous study. The difference might be due to differences in study settings and definitions of IPF. Further research should be performed to determine the prevalence more accurately and compare it with those in other countries. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01938-6.
format Online
Article
Text
id pubmed-8822670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88226702022-02-08 Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis Kondoh, Yasuhiro Suda, Takafumi Hongo, Yoshie Yoshida, Manami Hiroi, Shinzo Iwasaki, Kosuke Takeshima, Tomomi Homma, Sakae Respir Res Research BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a cryptogenic chronic interstitial pneumonia with progressive fibrosis and a poor prognosis. A substantial number of epidemiological studies have been conducted in Europe and the United States (US). In contrast, in Japan, only one study reported the prevalence of IPF (10.0 per 100,000 population) using clinical data (2003–2007) from one prefecture; thus, the nationwide prevalence of IPF remains unknown. This study aimed to estimate the nationwide prevalence of IPF in Japan using a nationwide claims database. METHODS: We extracted data from a Japanese claims database provided by Medical Data Vision (MDV database, April 2008–March 2019) containing data from approximately 28 million patients from 385 acute-care hospitals. Patients with IPF (those diagnosed with IPF at least once) from April 2017 to March 2018 were identified in the MDV database. The number of patients in the MDV database was extrapolated nationwide using the fourth NDB Open Data (April 2017–March 2018), and the prevalence was estimated using demographic data as denominators. The prevalence in the US, considering the same definition of IPF, was also calculated and compared with that in Japan. RESULT: The number of patients with IPF in the MDV database was 4278. The estimated nationwide number of patients in Japan was estimated to be 34,040 (mean age: 73 years, percentage of men: 73%), and the prevalence was 27 per 100,000 population. In comparison with that in the US, the prevalence was similar in men and relatively lower in women until the age of 75–79 years, and it was notably lower in both sexes aged ≥ 80 years. CONCLUSIONS: We report the nationwide IPF prevalence in Japan using data from claims databases for the first time. The prevalence estimated in this study was higher than that reported in a previous study. The difference might be due to differences in study settings and definitions of IPF. Further research should be performed to determine the prevalence more accurately and compare it with those in other countries. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01938-6. BioMed Central 2022-02-08 2022 /pmc/articles/PMC8822670/ /pubmed/35135550 http://dx.doi.org/10.1186/s12931-022-01938-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kondoh, Yasuhiro
Suda, Takafumi
Hongo, Yoshie
Yoshida, Manami
Hiroi, Shinzo
Iwasaki, Kosuke
Takeshima, Tomomi
Homma, Sakae
Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title_full Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title_fullStr Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title_full_unstemmed Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title_short Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
title_sort prevalence of idiopathic pulmonary fibrosis in japan based on a claims database analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822670/
https://www.ncbi.nlm.nih.gov/pubmed/35135550
http://dx.doi.org/10.1186/s12931-022-01938-6
work_keys_str_mv AT kondohyasuhiro prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT sudatakafumi prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT hongoyoshie prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT yoshidamanami prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT hiroishinzo prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT iwasakikosuke prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT takeshimatomomi prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis
AT hommasakae prevalenceofidiopathicpulmonaryfibrosisinjapanbasedonaclaimsdatabaseanalysis